MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cncr.35384

Медицинская библиотека · Cancer · 2024

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.

Haddad Fadi G, Sasaki Koji, Nasr Lewis, Short Nicholas J, Kadia Tapan, Dellasala Sara, Cortes Jorge, Nicolini Franck E, Issa Ghayas C, Jabbour Elias, Kantarjian Hagop

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

BACKGROUND

Ponatinib is a third-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with robust activity in Philadelphia chromosome-positive leukemias. Herein, we report the long-term follow-up of the phase 2 trial of ponatinib in chronic myeloid leukemia in chronic phase.

METHODS

Patients received ponatinib 30 to 45 mg/day. The primary end point was the rate of 6-month complete cytogenetic response (CCyR). The study was held in June 2014 because of the risk of cardiovascular toxicity, requiring patients to change TKI.

RESULTS

Fifty-one patients were treated with ponatinib (median dose, 45 mg/day). Median age was 48 years (range, 21-75); 30 (59%) had baseline cardiovascular comorbidities. Median treatment duration was 13 months (range, 2-25). Fourteen patients (28%) discontinued ponatinib because of toxicities, 36 (71%) after the Food and Drug Administration warning/study closure, and one for noncompliance. Dasatinib was the most frequently chosen second-line TKI (n = 34; 66%). Among 46 patients evaluable at 6 months, 44 (96%) achieved CCyR, 37 (80%) major molecular response, 28 (61%) MR4, and 21 (46%) MR4.5. The cumulative 6-month rates of CCyR, major molecular response, MR4, and MR4.5 were 96%, 78%, 50%, and 36%, respectively. Durable MR4 ≥24 or ≥60 months was observed in 67% and 51% of patients, respectively. The 24-month event-free survival rate was 97%. After a median follow-up of 128 months, the 10-year overall survival rate was 90%. Eight patients (16%) had serious grade 2 to 3 cardiovascular adverse events, leading to permanent discontinuation in five (10%).

CONCLUSION

Ponatinib yielded high cytogenetic and molecular responses in newly diagnosed chronic myeloid leukemia in chronic phase. Its use in the frontline setting is hindered by arterio-/vaso-occlusive and other severe toxicities.

Для цитирования: Haddad Fadi G, Sasaki Koji, Nasr Lewis, Short Nicholas J, Kadia Tapan, Dellasala Sara, Cortes Jorge, Nicolini Franck E, Issa Ghayas C, Jabbour Elias, Kantarjian Hagop. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.. Cancer. 2024. DOI: 10.1002/cncr.35384.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.